TrianglePUBLICATIONS · 19652067
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2009 Sep 10
- First author
- O'Connor OA
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- O'Connor OA
- type
- Author
- name
- Horwitz S
- type
- Author
- name
- Hamlin P
- type
- Author
- name
- Portlock C
- type
- Author
- name
- Moskowitz CH
- type
- Author
- name
- Sarasohn D
- type
- Author
- name
- Neylon E
- type
- Author
- name
- Mastrella J
- type
- Author
- name
- Hamelers R
- type
- Author
- name
- Macgregor-Cortelli B
- type
- Author
- name
- Patterson M
- type
- Author
- name
- Seshan VE
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- O'Connor OA
- type
- Author
- name
- Horwitz S
- type
- Author
- name
- Hamlin P
- type
- Author
- name
- Portlock C
- type
- Author
- name
- Moskowitz CH
- type
- Author
- name
- Sarasohn D
- type
- Author
- name
- Neylon E
- type
- Author
- name
- Mastrella J
- type
- Author
- name
- Hamelers R
- type
- Author
- name
- Macgregor-Cortelli B
- type
- Author
- name
- Patterson M
- type
- Author
- name
- Seshan VE
- type
- Author
- bibliography ids
- nci-bib-1fa143cbb6358ba3e996abcf
- book metadata
- content sha256
- 6f185987c00cf849337ea504d1f98da08bfa7e0704fdecf90178f026b608bd3f
- document type
- citation
- dois
- 10.1200/JCO.2008.20.8470
- electronic publication date
- display
- 2009 Aug 3
- precision
- day
- year
- 2009
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:19652067
- immutable id
- pubmed:19652067@6f185987c00cf849337ea504d1f98da08bfa7e0704fdecf90178f026b608bd3f
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 26
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 4357-64
- volume
- 27
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 19652067
- provenance
- batch id
- 0706b5111d1451f52f74
- provider
- NCBI PubMed ESummary
- record sha256
- 49aef52101dc13074a373efd4c37776fbb71287ba8d57cc69c5f0bf19d602ca7
- response sha256
- 98b7635e326dbc32198e6976da57b1b6c18df77505740dee0ce67d80260cda70
- retrieved at
- 2026-09-09T23:46:29.215195+00:00
- publication date
- display
- 2009 Sep 10
- precision
- day
- year
- 2009
- publication types
- Clinical Trial, Phase I
- Clinical Trial, Phase II
- Journal Article
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
Preserved source evidence · Independent clinical review pending · Not medical advice